Oxurion Receives Transparency Notifications
11 February 2023 - 05:30AM
Oxurion Receives
Transparency Notifications
Leuven, BELGIUM, Boston, MA, US
– February
10, 2022 –
7.30
PM CET Oxurion NV (Euronext
Brussels: OXUR) a biopharmaceutical company developing next
generation standard of care ophthalmic therapies, with clinical
stage assets in vascular retinal disorders, today announced that,
pursuant to Belgian Transparency legislation1 it has received a
transparency notification as follows:
Oxurion received a transparency notification on
February 9, 2023 from Negma Group Ltd. indicating that as of
February 3, 2023, it held 12,528,163 shares of the then outstanding
466,875,130 shares, and therefore crossed below the threshold (3%)
by virtue of disposal of voting securities. See Annex 1
Oxurion received a transparency notification on
February 8, 2023 from Negma Group Ltd. indicating that as of
February 1, 2023, it held 17,693,115 shares of the then outstanding
466,875,130 shares, and therefore crossed below the threshold (5%)
by virtue of disposal of voting securities. See Annex 2
In addition, Oxurion informs the markets that it
has updated the Transparency Notifications section of its investor
relations website
(https://ir.oxurion.com/shareholder-information/transparency-notifications)
to incorporate additional transparency notifications from Negma,
Thomas M. Clay/Epacria Capital Partners LLC and Philippe
Vlerick/Bareldam SA disclosing their positions having crossed below
the threshold (3%) by virtue of the issuance of new voting
securities in late 2022.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10 " tom.graney@oxurion.com Michael DillenChief Business
OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com |
USConway CommunicationsMary T.
Conwaymtconway@conwaycommsir.com ICR
WestwickeChristopher BrinzeyTel: +1 617 835
9304Chris.Brinzey@westwicke.com |
________
1. Article 14, first paragraph, of the Law of 2 May 2007 on
disclosure of major holdings.
ANNEX 1
ANNEX 2
- OXUR Transparency Notification (NL) 2023.2.8.FINAL
- OXUR Transparency Notification (EN) 2023.2.8.FINAL
Oxurion NV (EU:OXUR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oxurion NV (EU:OXUR)
Historical Stock Chart
From Mar 2023 to Mar 2024